Dipeptidylpeptidase 4 Inhibition Enhances Lymphocyte Trafficking, Improving Both Naturally Occurring Tumor Immunity and Immunotherapy

The Institut Pasteur

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application PCT/EP2015/079663, filed Dec 14, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 11,229,645	Dipeptidylpeptidase 4 Inhibition Enhances Lymphocyte Trafficking, Improving Both Naturally Occurring Tumor Immunity and Immunotherapy Institut National de la Sante et de la Recherche Medicale (Inserm) In force Term ends Dec 14, 2035 · High confidence	Institut National de la Sante et de la Recherche Medicale (Inserm)	In force	Term ends Dec 14, 2035	Term ends Dec 14, 2035	High confidence
US 11,883,398	Dipeptidylpeptidase 4 Inhibition Enhances Lymphocyte Trafficking, Improving Both Naturally Occurring Tumor Immunity and Immunotherapy Institut National de la Sante et de la Recherche Medicale (Inserm) In force Term ends Dec 14, 2035 · High confidence	Institut National de la Sante et de la Recherche Medicale (Inserm)	In force	Term ends Dec 14, 2035	Term ends Dec 14, 2035	High confidence
US 11,000,521	Dipeptidylpeptidase 4 Inhibition Enhances Lymphocyte Trafficking, Improving Both Naturally Occurring Tumor Immunity and Immunotherapy Institut Pasteur and Institut National de la Sante et de la Recherche Medicale (Inserm) In force Term ends Jan 20, 2036 · High confidence	Institut Pasteur and Institut National de la Sante et de la Recherche Medicale (Inserm)	In force	Term ends Jan 20, 2036	Term ends Jan 20, 2036	High confidence
US 11,357,831	Sequence-Specific Antimicrobials by Blocking DNA Repair Eligo Bioscience In force Term ends Sep 26, 2036 · High confidence	Eligo Bioscience	In force	Term ends Sep 26, 2036	Term ends Sep 26, 2036	High confidence
US 12,105,095	Assay to Detect and Quantitate Specific Antibodies for Various Redox Forms of HMGB1 Institut Pasteur In force Term ends Nov 9, 2036 · High confidence	Institut Pasteur	In force	Term ends Nov 9, 2036	Term ends Nov 9, 2036	High confidence
US 12,214,022	Sequence-Specific Antimicrobials by Blocking DNA Repair Eligo Bioscience In force Ends no later than May 14, 2037 · Medium confidence	Eligo Bioscience	In force	Ends no later than May 14, 2037	Ends no later than May 14, 2037	Medium confidence
US 11,460,473	Assay to Detect and Quantitate Specific Antibodies for Various Redox Forms of HMGB1 Institut Pasteur Lapsed Oct 4, 2026 on the fee record Ended Oct 4, 2026 · High confidence	Institut Pasteur	Lapsed Oct 4, 2026 on the fee record	Ended Oct 4, 2026	Ended Oct 4, 2026	High confidence
Application 15/744,039	Improving Sequence-Specific Antimicrobials by Blocking DNA Repair Institut Pasteur and Eligo Bioscience Abandoned Abandoned Nov 5, 2019	Institut Pasteur and Eligo Bioscience	Abandoned	Abandoned Nov 5, 2019	not computed
Application 18/532,790	Dipeptidylpeptidase 4 Inhibition Enhances Lymphocyte Trafficking, Improving Both Naturally Occurring Tumor Immunity and Immunotherapy Institut National de la Sante et de la Recherche Medicale (Inserm) Pending Not granted	Institut National de la Sante et de la Recherche Medicale (Inserm)	Pending	Not granted	not computed
Application 15/768,001	5-Hydroxytryptamine 1B Receptor-Stimulating Agent for the Treatment of Myocardial Infarction Université Paris Cité Abandoned Abandoned Jun 17, 2022	Université Paris Cité	Abandoned	Abandoned Jun 17, 2022	not computed

10 of 10 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

6 of these are in force and held by The Institut Pasteur.

Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.